Methylation status of RASSF1A in patients with chronic myeloid leukemia |
| |
| Authors: | Antigoni Avramouli Stefanos Tsochas Eudokia Mandala Eirini Katodritou Maria Ioannou Konstantinos Ritis Matthaios Speletas |
| |
| Affiliation: | 1. Department of Immunology and Histocompatibility, University of Thessaly Medical School, 41110 Larissa, Greece;2. D’ Department of Internal Medicine, Aristotle University of Thessaloniki, Greece;3. Hematology Department, Theagenion Anticancer Institute, Thessaloniki, Greece;4. Pathology Department, University of Thessaly Medical School, Larissa, Greece;5. A’ Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece;1. Whitehead Institute for Biomedical Research, Cambridge, MA;2. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA;3. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA;4. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA;5. Department of Physics, Massachusetts Institute of Technology, Cambridge, MA;6. Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, Utrecht, The Netherlands;7. University Medical Center Utrecht, Utrecht, The Netherlands;1. Division of Hematology, Oncology, and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany;;2. Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany;;3. Division of Hematology, Columbus, OH;;4. Division of Medical Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Columbus, OH;;5. Division of Hematopathology, Department of Pathology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH;;6. Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;;7. Division of Hematology-Oncology and Central Office of CLL Research Consortium, Moores Cancer Center, University of California San Diego, La Jolla, CA;;8. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;;9. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;;10. Institute of Cancer, Centre for Medical Oncology, Barts and The London School of Medicine, University of London, London, United Kingdom;;11. Division of Hematology-Oncology, North Shore-Long Island Jewish Health System, New Hyde Park, NY; and;12. Division of Hematology, Mayo Clinic, Rochester, MN;1. Laboratoire des Sciences du Climat et de l''Environnement/IPSL, CEA-CNRS-UVSQ, Avenue de la Terrasse, 91198 Gif-sur-Yvette Cédex, France;2. Departamento de Física-Geología, Universidad de Las Palmas de Gran Canaria, 35017 Las Palmas de Gran Canaria, Spain;3. Institute of Earth Sciences Jaume Almera, ICTJA-CSIC, Sole i Sabaris s/n, 08028 Barcelona, Spain;1. Lehrstuhl für Geomorphologie, Universität Bayreuth, D-95440 Bayreuth, Germany;2. BayCEER, Universität Bayreuth, D-95440 Bayreuth, Germany;3. Institute for Oriental and European Archaeology, Austrian Academy of Sciences, Fleischmarkt 22, 1010 Vienna, Austria;1. Massey Cancer Center, Virginia Commonweath University, Richmond, VA;2. Department of Microbiology and Immunology, Virginia Commonweath University, Richmond, VA;3. Department of Human and Molecular Genetics, Virginia Commonweath University, Richmond, VA;4. Department of Pathology, Virginia Commonweath University, Richmond, VA;5. Department of Internal Medicine, Virginia Commonweath University, Richmond, VA |
| |
| Abstract: | RASSF1A, a key cell cycle related gene, is expressed in all hematopoietic cells, it is implicated in ras signaling pathway and its promoter hypermethylation is observed in a wide variety of solid tumors. Till now, RASSF1A methylation status has not been investigated in patients with chronic myeloid leukemia (CML). In this study, we analyzed 41 patients carrying the BCR-ABL rearrangement, in different stages of the disease. No patient displayed RASSF1A promoter methylation, although the K562 erythroleukemia cell line, bearing the BCR-ABL rearrangement, was found methylated. Thus, our findings indicate that RASSF1A methylation does not appear to represent a critical step in the pathogenesis and/or the progression of CML. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
